The daily De Telegraaf on Saturday published a statement by Onno van De Stolpe, CEO of Belgium-based biotech Galapagos, according to which the group is 50% likely to be acquired by a competitor over the next 10 years. The chief executive considers California-based Gilead, which is already among its minority stakeholders, as the most likely buyer of Galapagos’. Moreover, the Dutch manager estimates that his company, currently valued at €5bn, will soon reach a capitalization comparable to Philips’ one, that is €30bn. Going forward, Galapagos’ success will almost completely depend on its investigational rheumatoid arthritis treatment filgotinib, expected to be launched on the market in 2020.
(Source: De Telegraaf)